The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. NRX Pharmaceuticals Inc shares valued at $46,800 were purchased by Javitt Jonathan C on Dec 17 ’24. At $1.17 per share, Javitt Jonathan C acquired 40,000 shares. The insider’s holdings grew to 84,634 shares worth approximately $0.27 million following the completion of this transaction.
As published in their initiating research note from BTIG Research on April 02, 2025, NRX Pharmaceuticals Inc [NRXP] has been a Buy and the price target has been revised to $18.
Analyzing NRXP Stock Performance
On last trading session,, NRX Pharmaceuticals Inc [NASDAQ: NRXP] plunged -3.29% to $3.23. The stock’s lowest price that day was $3.23, but it reached a high of $3.42 in the same session. During the last five days, there has been a drop of approximately -7.18%. Over the course of the year, NRX Pharmaceuticals Inc shares have jumped approximately 46.82%. Shares of the company reached a 52-week high of $6.01 on 01/13/25 and a 52-week low of $1.58 on 04/07/25.
Support And Resistance Levels for NRX Pharmaceuticals Inc (NRXP)
According to the 24-hour chart, there is a support level at 3.17, which, if violated, would cause prices to drop to 3.10. In the upper region, resistance lies at 3.36. The next price resistance is at 3.48. RSI (Relative Strength Index) is 60.86 on the 14-day chart, showing neutral technical sentiment.
Is NRX Pharmaceuticals Inc subject to short interest?
Stocks of NRX Pharmaceuticals Inc saw a sharp steep in short interest on 2025-05-30 dropping by 99637.0 shares to 1.11 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 1.21 million shares. A decline of -8.95% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.15 of the overall float, the days-to-cover ratio (short ratio) decline to 3.15.
Which companies own the most shares of NRX Pharmaceuticals Inc (NRXP)?
In terms of NRX Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 2 in the next 12 months, down nearly -40.12% from the previous closing price of $3.34. Analysts anticipate NRX Pharmaceuticals Inc stock to reach 2 by 2025, with the lowest price target being 2. In spite of this, 1 analysts ranked NRX Pharmaceuticals Inc stock as Buy at the end of 2025.
